Jianwen Huang
King & Wood Mallesons
King & Wood Mallesons
Client SatisfactionKing & Wood Mallesons is a ‘trusted partner’ for Chinese and international clients across the pharmaceutical, biotech, hospital, and medical devices sectors, as well as for investors in these industries. Led by Jianwen Huang, the group offers a wide range of legal services, including M&A, IPOs, compliance, and licensing. Yuanyuan Zhu and Ting Liu support healthcare and pharmaceutical clients with anti-commercial bribery investigations and establishing compliance systems. Mark Zhang brings extensive expertise in M&A, clinical trials, and drug licensing transactions. Fan Yang departed the firm in February 2024.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘The team has extensive industry experience in providing legal advice for corporate compliance.’
'Mark Zhang and Zhongbin Huang all provide excellent service quality and can understand the needs of enterprises.’
‘The team has extensive experience in transactions, regulation and other areas in the life science and healthcare industries, and can handle some controversial issues such as clinical trial disputes compared to other teams. They have experience in serving first-tier MNCs and domestic biotech firms, and can provide practical guidance relatively quickly.’
‘Mark Zhang has long-term experience in serving MNCs and Chinese biotech clients.’
‘King & Wood Mallesons has extensive experience in the life sciences and healthcare sectors, covering transactions, regulatory compliance, investigations, clinical trials and medical disputes. Their collaboration with major multinational pharmaceutical companies and first-tier biopharmaceutical startups makes them a trusted partner in the industry.’
‘Mark Zhang has extensive expertise in life sciences and healthcare law. He is familiar with transactions, regulatory compliance, investigations, clinical trials, and medical disputes. With his in-depth industry insights and innovative thinking, he provides clients with excellent legal solutions.’
‘Mark Zhang's team has extensive experience in transactions, regulatory compliance and other areas in the life sciences and healthcare industries. The team is able to cope with various daily legal needs of our company.’
‘Solid legal expertise and a thorough understanding of business demands.’
Key clients
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Haier Group Corporation
- Reckitt Benckiser Group plc
- Novo Nordisk A/S
- Teva
- Astellas Pharma Inc./Pfizer
- Novartis AG
- Koninklijke Philips N.V., Philips (China) Investment Co., Ltd.
- China National Medical Device Co., Ltd.
Work highlights
- Represented Haier Group on its acquisition of 20% shares and 6.58% voting rights in Shanghai RAAS Blood Products Co., Ltd., held by Grifols S.A.
- Represented Novo Nordisk in Semaglutide Compound Patent invalidation, in which SIPO revoked its review decision on invalidating said patent.
- Advised Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. on its USD174m H share IPO, acting as PRC legal advisor to the issuer.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Mark Zhang
King & Wood MallesonsNext Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Yuanyuan Zhu
King & Wood MallesonsTing Liu
King & Wood MallesonsPractice head
The lawyer(s) leading their teams.
Jianwen Huang